Matches in Wikidata for { <http://www.wikidata.org/entity/Q65376378> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- Q65376378 description "assaig clínic" @default.
- Q65376378 description "clinical trial" @default.
- Q65376378 description "clinical trial" @default.
- Q65376378 description "clinical trial" @default.
- Q65376378 description "clinical trial" @default.
- Q65376378 description "ensaio clínico" @default.
- Q65376378 description "ensayo clínico" @default.
- Q65376378 description "ensayu clínicu" @default.
- Q65376378 description "essai clinique" @default.
- Q65376378 description "klinisch onderzoek" @default.
- Q65376378 description "клінічне випробування" @default.
- Q65376378 name "A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)" @default.
- Q65376378 name "A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma" @default.
- Q65376378 type Item @default.
- Q65376378 label "A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)" @default.
- Q65376378 label "A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma" @default.
- Q65376378 prefLabel "A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)" @default.
- Q65376378 prefLabel "A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma" @default.
- Q65376378 P1050 Q65376378-EA0A5594-4484-47A4-8816-8C9FDF407103 @default.
- Q65376378 P1132 Q65376378-91FC70FA-E65C-4089-9169-77520FA5F91D @default.
- Q65376378 P1476 Q65376378-80E3E38E-3D32-44F4-B8FB-4B1978C8E454 @default.
- Q65376378 P17 Q65376378-0EBD7F11-17F9-4645-BDCE-E36676EB8FF8 @default.
- Q65376378 P17 Q65376378-2518295C-202A-4A08-A63B-3BC915223C59 @default.
- Q65376378 P17 Q65376378-2E1D3718-E8C5-48C2-99F2-8B965F0D7457 @default.
- Q65376378 P17 Q65376378-37F6C769-93D0-4322-942C-468FC0A088A3 @default.
- Q65376378 P17 Q65376378-3BF97DA5-DFD3-4AC3-8318-A06F027A80C1 @default.
- Q65376378 P17 Q65376378-5242AC6F-EBF8-4D58-8135-393948E76512 @default.
- Q65376378 P17 Q65376378-5C81F325-C266-4DF2-A7A6-A2AFE7344011 @default.
- Q65376378 P17 Q65376378-79EB4A3E-6531-459D-8316-CBC8B8A37B80 @default.
- Q65376378 P17 Q65376378-7EBFCBA9-B422-45B8-A08B-733528FDB6C4 @default.
- Q65376378 P17 Q65376378-8260D599-78A8-44E8-B7B1-65DDF7D8B2A0 @default.
- Q65376378 P17 Q65376378-BA3414BA-B96C-4BD7-B612-DFDBF8D07381 @default.
- Q65376378 P17 Q65376378-BED80486-27A6-4180-A2C0-F77206B4140B @default.
- Q65376378 P17 Q65376378-DA849CE3-BDEF-4BFD-898C-E6D87EA5C74C @default.
- Q65376378 P17 Q65376378-DDD77C11-0C47-4C65-B9CB-60DC78254E9C @default.
- Q65376378 P2899 Q65376378-265F2621-0916-4124-8052-552D4F60768C @default.
- Q65376378 P3098 Q65376378-6ABED354-CD6F-4DCC-B092-8B21AE77CFD9 @default.
- Q65376378 P31 Q65376378-71B3AEEA-1FDA-42A4-B454-133F3E45093C @default.
- Q65376378 P580 Q65376378-A8AEB2D7-2256-495B-8726-7E21FAE33CCF @default.
- Q65376378 P582 Q65376378-E6A4CFA9-30CF-4526-BC91-531753045262 @default.
- Q65376378 P6099 Q65376378-C5FC8E5B-8AF7-42EF-8A6B-7929D08EA4C2 @default.
- Q65376378 P6153 Q65376378-1C097721-4501-468D-9055-3945029A70E9 @default.
- Q65376378 P6153 Q65376378-651888B4-CEAE-4A0B-8088-ECAAB28E57BD @default.
- Q65376378 P6153 Q65376378-65A83555-8841-4A88-80E5-64ED1550FF2E @default.
- Q65376378 P6153 Q65376378-7A3BB6E4-9172-4983-A631-381FF2ED674F @default.
- Q65376378 P6153 Q65376378-B45D678C-B405-45FE-BA8B-C49CFC46A680 @default.
- Q65376378 P6153 Q65376378-F4FB1CEE-D3C2-4B54-B162-360D1503E2B8 @default.
- Q65376378 P8363 Q65376378-4BB63849-919D-47BC-8C1B-7F119DD571E9 @default.
- Q65376378 P921 Q65376378-7EA75B9F-9117-4186-B015-46B8CF3783BD @default.
- Q65376378 P1050 Q356033 @default.
- Q65376378 P1132 "+367" @default.
- Q65376378 P1476 "A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma" @default.
- Q65376378 P17 Q142 @default.
- Q65376378 P17 Q145 @default.
- Q65376378 P17 Q155 @default.
- Q65376378 P17 Q16 @default.
- Q65376378 P17 Q183 @default.
- Q65376378 P17 Q20 @default.
- Q65376378 P17 Q212 @default.
- Q65376378 P17 Q30 @default.
- Q65376378 P17 Q31 @default.
- Q65376378 P17 Q34 @default.
- Q65376378 P17 Q38 @default.
- Q65376378 P17 Q408 @default.
- Q65376378 P17 Q414 @default.
- Q65376378 P17 Q55 @default.
- Q65376378 P2899 "+18" @default.
- Q65376378 P3098 "NCT01124786" @default.
- Q65376378 P31 Q30612 @default.
- Q65376378 P580 "2010-05-01T00:00:00Z" @default.
- Q65376378 P582 "2012-11-01T00:00:00Z" @default.
- Q65376378 P6099 Q42824440 @default.
- Q65376378 P6153 Q1776898 @default.
- Q65376378 P6153 Q2936440 @default.
- Q65376378 P6153 Q30270115 @default.
- Q65376378 P6153 Q30270311 @default.
- Q65376378 P6153 Q5188247 @default.
- Q65376378 P6153 Q6806307 @default.
- Q65376378 P8363 Q78089383 @default.
- Q65376378 P921 Q27164708 @default.